Elementa Labs: 2022 in Review
Take a look at the exciting updates from the past year of Elementa Labs! In 2022, MSIP witnessed the growth of several Elementa portfolio companies from its first two cohorts: the inaugural Fall 2021 and Spring 2022. These companies have continued to …
Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney Disease
Risk scoring by KidneyIntelX resulted in a 4.5-fold increase in new drug prescriptions (for SGLT2 inhibitors) for high risk compared to low risk patients, an observed reduction of HbA1c levels in the highest risk patients, an overall increased use of antihypertensive therapeutics, …
New Blood Test Delivers Highly Accurate Threshold Assay That Enhances Clinical Management for Peanut Allergy
Allergenis’ bead-based epitope assay at center of study from Mount Sinai revealing breakthrough diagnostic for peanut allergy. Allergenis, a predictive data analytics company specializing in the detection and management of life-threatening food allergies, today announced the results of extensive research and development …
Mount Sinai Awarded $11.6 Million Grant to Launch Comprehensive Center for Surgical Innovation and Expand Mount Sinai BioDesign
Work will benefit patients, contribute to job creation and economic growth in New York City. In a move that has the potential to change the future of surgery, advance quality care, and bring economic growth to New York City, Mount Sinai Health …
Mount Sinai Announces the Formation of CastleVax Inc., a Clinical-Stage Infectious Diseases Company Developing Novel Vaccines and Therapeutics, Targeting Pandemic Threats and Diseases of Unmet Medical Need
The Mount Sinai Health System in New York, NY, has launched CastleVax, Inc. (“CastleVax”), a clinical-stage vaccine research and development company. CastleVax is devoted to the commercial development of the Newcastle disease virus (NDV) vaccine platform technology originally developed in the laboratories …
Gromit Therapeutics Announces an Exclusive License Agreement with the Icahn School of Medicine at Mount Sinai
Gromit Therapeutics, a clinical-stage biopharmaceutical company, developing disruptive gene therapies for inflammatory and age related diseases, and the Icahn School of Medicine at Mount Sinai in New York , NY (“Icahn Mount Sinai”) have announced today an exclusive license agreement to the …
1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX™ Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease Patients
Late-breaking data presented at American Diabetes Association Scientific Sessions® demonstrates increased adherence to care guidelines for physicians using KidneyIntelX risk assessment to improve outcomes, alleviate patient suffering, and reduce significant financial burden associated with rapidly progressing chronic kidney disease. Deployment of Renalytix’s …
Mount Sinai Elementa Labs: First Year in Review
Take a look at the exciting updates from the inaugural year of Elementa Labs, Mount Sinai’s virtual incubator program. Elementa Labs is currently accepting new applications for the Spring 2023 cohort until August 1. Learn more and apply here. In May 2021, …
Renalytix Announces Two Data Presentations on KidneyIntelX™ at American Diabetes Association 82nd Scientific Sessions®
Real-world clinical utility in 1,112 patients tested with KidneyIntelX. KidneyIntelX stratification for cardiovascular risk in 1,278 diabetic kidney disease patients Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced its participation at the American Diabetes Association (ADA) 82nd Scientific Sessions® meeting in New Orleans from …